Table 2. Baseline laboratory results.
| Overall n/N (%) | Approved n/N (%) | Denied n/N (%) | ||||
| Characteristics | N = 410 | N = 332 | N = 78 | OR | 95% CI | p-Value |
| Genotype | 0.803 | |||||
| 1 | 349/410 (85.1%) | 283/332 (85.2%) | 66/78 (84.6%) | Reference | ||
| 2 | 22/410 (5.4%) | 19/332 (5.7%) | 3/78 (3.8%) | 1.48 | 0.49–6.42 | |
| 3 | 30/410 (7.3%) | 23/332 (6.9%) | 7/78 (9.0%) | 0.77 | 0.33–2 | |
| 4 | 9/410 (2.2%) | 7/332 (2.1%) | 2/78 (2.6%) | 0.82 | 0.19–5.56 | |
| Viral load (IU/mL) Median (IOR) | 2,010,000 (579,500–5,405,000) | 2,100,000 (57,8750–5,585,000) | 1702,612 (662,000–4,310,000) | – | – | 0.579 |
| AST (U/L) Median (IQR) | 46.5 (32–76.2) | 48 (31–77) | 45 (35.2–72.8) | – | – | 0.644 |
| ALT (U/L) Median (IQR) | 54 (32–89) | 54 (30–89.5) | 58.5 (39–87.8) | – | – | 0.197 |
| Bilirubin, Total (mg/dL) Median (IQR) | 0.5 (0.4–0.8) | 0.6 (0.4–0.8) | 0.5 (0.4–0.9) | – | – | 0.37 |
| Alkaline phosphatase (U/L) Median (IQR) | 83 (63–111) | 86 (65.2–114) | 73 (59.2–100) | – | – | 0.027 |
| Albumin (g/dL) Median (IQR) | 4.3 (3.8–4.5) | 4.2 (3.8–4.4) | 4.4 (4–4.6) | – | – | 0.002 |
| Platelet count (x10E3/uL) Median (IQR) | 169 (109.5–227) | 161 (103–223) | 181 (141.5–238.5) | – | – | 0.019 |
| Creatinine (mg/dL) Median (IQR) | 0.9 (0.8–1.1) | 0.9 (0.8–1.1) | 0.8 (0.7–1) | – | – | 0.077 |
| INR Median (IQR) | 1.1 (1.1–1.2) | 1.1 (1–1.2) | 1.1 (1.1–1.2) | – | – | 0.89 |
Abbreviations: AST, Aspartate Transaminase; ALT, Alanine Transaminase; INR, International Normalized Ratio; IQR, Interquartile Range.